Photo by atikahakhtar from unsplash
Erytrhodermic psoriasis (EP) is a rare subset of psoriasis that is considered a dermatologic emergency. Due to its limited clinical evidence, pathogenesis is largely unknown and its treatment represents a… Click to show full abstract
Erytrhodermic psoriasis (EP) is a rare subset of psoriasis that is considered a dermatologic emergency. Due to its limited clinical evidence, pathogenesis is largely unknown and its treatment represents a challenge. Conventional therapies such as methotrexate, cyclosporine, and acitretin are still considered first‐line of treatment but it is necessary to study the efficacy and safety of biologics, including antitumor necrosis factor (TNF), anti‐interleukin (IL)‐23, and anti‐IL17 agents to define new guidelines of treatment. Here, we report two cases of patients with EP treated with ixekizumab.
Journal Title: Dermatologic Therapy
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!